{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T10:49:10Z","timestamp":1791888550624,"version":"4.3.4"},"reference-count":60,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Respir Dis"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:p>Severe asthma affects 5\u201310% of children with asthma yet accounts for disproportionate morbidity and healthcare utilisation. The recent expansion of biologic therapies\u2014targeting IgE, IL-5, IL-4\/13, TSLP, and IL-5 receptor \u03b1\u2014has transformed management but introduced complexity into clinical decision-making. This review provides a comprehensive, comparative analysis of currently approved biologic agents for paediatric severe asthma, with emphasis on efficacy, safety, biomarker-guided selection, and practical implementation. We searched PubMed\/MEDLINE (2015\u20132026) for randomised controlled trials, systematic reviews, and observational studies evaluating biologic therapies in children and adolescents with severe asthma, using a narrative synthesis approach.Five biologic agents are currently approved for paediatric severe asthma. Omalizumab (anti-IgE) reduces exacerbations by 38\u201350% in allergic asthma (\u22656 years). Mepolizumab (anti-IL-5) reduces exacerbations by 27% (rate ratio 0.73; 95% CI 0.56\u20130.96) in eosinophilic asthma in children and adolescents aged 6\u201317 years (MUPPITS-2). Dupilumab (anti-IL-4R\u03b1) reduces exacerbations by 59% and improves lung function in children 6\u201311 years (VOYAGE). Tezepelumab (anti-TSLP) reduces exacerbations by 56% and is the first agent effective in T2-low phenotypes (\u226512 years; NAVIGATOR). Benralizumab (anti-IL-5R\u03b1) induces near-complete eosinophil depletion with extended every-8-week maintenance dosing; FDA approval was extended to children \u22656 years in April 2024 based on the TATE trial (SIROCCO\/CALIMA\/BORA\/TATE). Safety profiles are generally favourable; dupilumab-associated conjunctivitis and omalizumab-related anaphylaxis require specific monitoring protocols.Biologic therapies have ushered paediatric severe asthma into the precision medicine era. Dupilumab and tezepelumab demonstrate robust efficacy across multiple phenotypes, while biomarker assessment enables rational, individualised selection.<\/jats:p>","DOI":"10.1177\/17534666261497070","type":"journal-article","created":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T15:04:10Z","timestamp":1791644650000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Individualising biologic therapy for paediatric severe asthma: A comparative review of all five approved agents, real-world evidence, and a biomarker-guided clinical decision algorithm"],"prefix":"10.1177","volume":"20","author":[{"given":"Xiaowei","family":"Yao","sequence":"first","affiliation":[{"name":"Zhongda Hospital Lishui Branch, Southeast University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4717-6579","authenticated-orcid":false,"given":"Yang","family":"Yu","sequence":"additional","affiliation":[{"name":"Zhongda Hospital Lishui Branch, Southeast University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,10,10]]},"reference":[{"key":"e_1_3_7_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)02125-0"},{"key":"e_1_3_7_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2021.11.010"},{"key":"e_1_3_7_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2014.06.022"},{"key":"e_1_3_7_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)33311-1"},{"key":"e_1_3_7_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/all.14425"},{"key":"e_1_3_7_7_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00202013"},{"key":"e_1_3_7_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40272-019-00345-7"},{"key":"e_1_3_7_9_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.108.2.e36"},{"key":"e_1_3_7_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009705"},{"key":"e_1_3_7_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2015.09.008"},{"key":"e_1_3_7_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2014.12.1942"},{"key":"e_1_3_7_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.07.035"},{"issue":"1","key":"e_1_3_7_14_2","first-page":"CD003559","article-title":"Omalizumab for asthma in adults and children","author":"Normansell R","year":"2014","unstructured":"Normansell R, Walker S, Milan SJ, et al. Omalizumab for asthma in adults and children. Cochrane Database Syst Rev 2014; 1: CD003559. https:\/\/doi.org\/10.1002\/14651858.CD003559.pub4","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_7_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.03.002"},{"key":"e_1_3_7_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1403290"},{"key":"e_1_3_7_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60988-X"},{"key":"e_1_3_7_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)01198-9"},{"key":"e_1_3_7_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2019.08.005"},{"key":"e_1_3_7_20_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13223-019-0366-x"},{"key":"e_1_3_7_21_2","first-page":"100638","article-title":"Real-world impact of mepolizumab on pediatric and adolescent patients with severe asthma","author":"Hernandez ML","year":"2025","unstructured":"Hernandez ML, Lassiter S, Martin CJ, et al. Real-world impact of mepolizumab on pediatric and adolescent patients with severe asthma. J Allergy Clin Immunol Glob 2025: 100638. https:\/\/doi.org\/10.1016\/j.jacig.2025.100638","journal-title":"J Allergy Clin Immunol Glob"},{"key":"e_1_3_7_22_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1304048"},{"key":"e_1_3_7_23_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2106567"},{"key":"e_1_3_7_24_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804093"},{"key":"e_1_3_7_25_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804092"},{"issue":"8","key":"e_1_3_7_26_2","first-page":"2621","article-title":"Dupilumab efficacy in adolescents with uncontrolled, moderate-to-severe asthma","volume":"76","author":"Maspero JF","year":"2021","unstructured":"Maspero JF, Katelaris CH, Busse WW, et al. Dupilumab efficacy in adolescents with uncontrolled, moderate-to-severe asthma. LIBERTY ASTHMA QUEST. Allergy 2021; 76(8): 2621\u20132624. https:\/\/doi.org\/10.1111\/all.14872","journal-title":"LIBERTY ASTHMA QUEST. Allergy"},{"key":"e_1_3_7_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/pai.70196"},{"key":"e_1_3_7_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(21)00322-2"},{"key":"e_1_3_7_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2020.12.059"},{"key":"e_1_3_7_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2019.08.050"},{"key":"e_1_3_7_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.waojou.2026.101251"},{"key":"e_1_3_7_32_2","first-page":"608","article-title":"The assessment of dupilumab in children with moderate-to-severe asthma and comorbid type 2 inflammatory diseases","volume":"24","author":"Liu X","year":"2024","unstructured":"Liu X, Zhang Y, Li C, et al. The assessment of dupilumab in children with moderate-to-severe asthma and comorbid type 2 inflammatory diseases. BMC Pulm Med 2024; 24: 608. https:\/\/doi.org\/10.1186\/s12890-024-03414-x","journal-title":"BMC Pulm Med"},{"key":"e_1_3_7_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(21)00226-5"},{"key":"e_1_3_7_34_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1704064"},{"key":"e_1_3_7_35_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034975"},{"key":"e_1_3_7_36_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202210-2005OC"},{"key":"e_1_3_7_37_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-024-02889-8"},{"key":"e_1_3_7_38_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2026.1757754"},{"key":"e_1_3_7_39_2","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2022.2074195"},{"key":"e_1_3_7_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31324-1"},{"key":"e_1_3_7_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31322-8"},{"key":"e_1_3_7_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(18)30406-5"},{"key":"e_1_3_7_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.02.009"},{"key":"e_1_3_7_44_2","doi-asserted-by":"publisher","DOI":"10.1111\/pai.14092"},{"key":"e_1_3_7_45_2","doi-asserted-by":"publisher","DOI":"10.2147\/JAA.S270298"},{"key":"e_1_3_7_46_2","article-title":"Tezepelumab for oral corticosteroid-dependent severe asthma (WAYFINDER): a multicentre, open-label, single-arm, phase 3 trial","author":"Jackson DJ","year":"2025","unstructured":"Jackson DJ, Akar-Ghibril N, Chipps BE, et al. Tezepelumab for oral corticosteroid-dependent severe asthma (WAYFINDER): a multicentre, open-label, single-arm, phase 3 trial. Lancet Respir Med 2025. https:\/\/doi.org\/10.1016\/S2213-2600(25)00178-X","journal-title":"Lancet Respir Med"},{"key":"e_1_3_7_47_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1703501"},{"key":"e_1_3_7_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2022.05.024"},{"key":"e_1_3_7_49_2","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2019.00256"},{"key":"e_1_3_7_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2021.10.001"},{"key":"e_1_3_7_51_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1608969"},{"key":"e_1_3_7_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.09.033"},{"key":"e_1_3_7_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2016.08.054"},{"key":"e_1_3_7_54_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1403291"},{"key":"e_1_3_7_55_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2466-13-11"},{"key":"e_1_3_7_56_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2021.04.013"},{"key":"e_1_3_7_57_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30397-0"},{"key":"e_1_3_7_58_2","doi-asserted-by":"publisher","DOI":"10.1002\/iid3.70023"},{"key":"e_1_3_7_59_2","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00709-2024"},{"key":"e_1_3_7_60_2","doi-asserted-by":"publisher","DOI":"10.1111\/resp.13026"},{"issue":"8","key":"e_1_3_7_61_2","first-page":"e082027","article-title":"Treating severe paediatric asthma with mepolizumab or omalizumab: a protocol for the TREAT randomised non-inferiority trial","volume":"14","author":"Pike KC","year":"2024","unstructured":"Pike KC, Turner S, Smith J, et al. Treating severe paediatric asthma with mepolizumab or omalizumab: a protocol for the TREAT randomised non-inferiority trial. BMJ Open 2024; 14(8): e082027. https:\/\/doi.org\/10.1136\/bmjopen-2023-082027","journal-title":"BMJ Open"}],"container-title":["Therapeutic Advances in Respiratory Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17534666261497070","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17534666261497070","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17534666261497070","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T10:17:44Z","timestamp":1791886664000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17534666261497070"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":60,"alternative-id":["10.1177\/17534666261497070"],"URL":"https:\/\/doi.org\/10.1177\/17534666261497070","relation":{"has-review":[{"id-type":"doi","id":"10.1177\/17534666261497070\/v3\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/17534666261497070\/v3\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/17534666261497070\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/17534666261497070\/v2\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/17534666261497070\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/17534666261497070\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/17534666261497070\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/17534666261497070\/v1\/review1","asserted-by":"object"}]},"ISSN":["1753-4666","1753-4666"],"issn-type":[{"value":"1753-4666","type":"print"},{"value":"1753-4666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10]]},"article-number":"17534666261497070"}}